Showing 6441-6450 of 8473 results for "".
- DermMentors™ 2017 Resident of Distinction Award Honors Five Dermatology Residentshttps://practicaldermatology.com/news/dermmentors-2017-resident-of-distinction-award-honors-five-dermatology-residents/2458273/As part of the dermMentors™ Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 16th Annual Caribbean Dermatology Symposium in Aruba, Netherlands Antilles, from January 17 - 21, 2017
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- Medical Spa State of the Industry Statistical Study Now Openhttps://practicaldermatology.com/news/medical-spa-state-of-the-industry-statistical-study-now-open/2458301/During the past five years, the medical spa industry has grown and evolved to a point where it has become one of the most exciting and lucrative new industries in the country. Because of this, it is now more important than ever that the industry have its own credible state of the industry report.
- Valeant Dermatology to Award $10,000 Scholarships for Undergraduate and Graduate Degreeshttps://practicaldermatology.com/news/valeant-dermatology-to-award-10000-scholarships-for-undergraduate-and-graduate-degrees/2458302/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, will award nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program. The scholarships will be awarded to students who will be attending undergraduate or graduate education progr
- Radiesse Hits Double Digitshttps://practicaldermatology.com/news/radiesse-hits-double-digits/2458312/Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back to 2007 when the first iPhone was released to the publi
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- PuraCap Rolls Out Two New Acne Productshttps://practicaldermatology.com/news/puracap-rolls-out-two-new-acne-products/2458351/PuraCap Pharmaceutical LLC is rolling out two new acne products, Eptex Controlled Release Acne Wash and Eptex Controlled Release Acne Relief Lotion. Available through healthcare professionals, the products utilize a controlled release Intelli-Tar
- Novan: Significant Improvement of Genital Warts with SB206https://practicaldermatology.com/news/novan-significant-improvement-of-genital-warts-with-sb206/2458355/Top-line results from Novan Inc.’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV show statistically significant benefits, the company reports. The highest dose tested, SB206 12%, demonstrated a st